

# Review of: "Long-Term Risk of Medication-Related Osteonecrosis of the Jaw (MRONJ) After Bisphosphonates and/or Denosumab in Metastatic Breast Cancer Patients"

Sven Nørholt<sup>1</sup>

<sup>1</sup> Dept of Dentistry and Oral Health, Aarhus University, Aarhus Denmark, Aarhus University Hospital, Århus, Denmark

Potential competing interests: No potential competing interests to declare.

The paper is a highly relevant exploration of the results from a long-term study on breast cancer treatment. The elaboration on the data is extremely important for all clinicians involved in the treatment of MRONJ and, additionally, raises important considerations about the length of antiresorptive treatment.

The increased risk of MRONJ in patients treated with Denosumab should be noted by all oncologists and taken into consideration when choosing the type of medication. This finding was also presented in a paper by Ehrenstein in 2021 ([Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden Ehrenstein, V., Heide-Jørgensen, U., Schiødt, M., Akre, O., Herlofson, B. B., Hansen, S., Larsson Wexell, C., Nørholt, S. E., Tretli, S., Kjellman, A., Glennane, A., Lowe, K. A. & Sørensen, H. T., nov. 2021, I: \*Cancer\*. 127, 21, s. 4050-4058](#))